Back

Highlights from HELIOS-B - Primary results from phase 3 study of vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy

31 August 2024 (18:22 - 18:33)
Organised by: Logo
Congress Presentation Part of: Daily Highlights by the Argentine Society of Cardiology European Society of Cardiology ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Diego Perez de Arenaza

Italian Hospital of Buenos Aires, Buenos Aires (Argentina)

3 More presentations in this session

Presentation thumbnail
Highlights from RESHAPE-HF2 - Percutaneous repair of moderate-to-severe or severe functional mitral regurgitation in patients with symptomatic heart failure
Doctor A. Salvati (Moron, Buenos Aires, AR)
Slides Video
Presentation thumbnail
Highlights from Tri. fr trial - Multicentric randomised evaluation of the transcatheter edge-to-edge repair in the treatment of severe isolated secondary tricuspid regurgitation
Doctor J. Costabel (Buenos Aires, AR)
Slides Video
Presentation thumbnail
Daily Highlights by the Argentine Society of Cardiology - panel discussion
Video

Access the full session

Session thumbnail
Daily Highlights by the Argentine Society of Cardiology
Video

The Event

Event poster

ESC Congress 2024

31 August 2024 18:22 CET
You may be interested in
thumbnail
Congress Presentation
HELIOS-B - Primary results from phase 3 study of vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy
thumbnail
Congress Presentation
Highlights from HELIOS-B - Primary results from phase 3 study of vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy
thumbnail
Congress Presentation
HELIOS-B: 12-month results from the open-label extension period of vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources